Aldesleukin
Definition
Aldesleukin is interleukin, or specific kind of biological response modifier, that is used to treat metastatic renal cell carcinoma (a form of kidney cancer) and metastatic melanoma. Aldesleukin is also known as interleukin-2, IL-2 and the trademarked name Proleukin.
Purpose
When renal cell carcinoma and metastatic melanoma (cancer of the skin that arises in the pigmented cells of the skin or eyes) do not respond to other therapies, they are candidates for treatment with aldesleukin.
Description
Aldesleukin is a biological response modifier (BMR). It promotes the development of T cells, or the cells in the lymphatic system that can fight cancer cells in cell-to-cell interaction. The human body produces aldesleukin naturally.
For use in therapy, aldesleukin is manufactured in a laboratory setting, using biotechnology methods, or methods that combine biological mechanisms and tools from technology. In the instance of aldesleukin, the compound is made in large quantities by using recombinant DNA technology. The DNA, or hereditary material, that provides instructions for making aldesleukin, is put in bacterial cells under laboratory confinement. The cells then produce large quantities of the human compound that are harvested, purified, and used for treatment.
Treatment with aldesleukin is considered palliative, which means it provides comfort but does not produce a cure. In some cases, aldesleukin is used together with an anticancer drug.
Recommended dosage
Standard treatment with aldesleukin is via an intravenous line. The standard dose is 0.037 milligrams per kilogram of body weight every eight hours. For renal cancer, up to 15 doses can be repeated over 7-10 days every 5-6 weeks. But because the aldesleukin has such severe side effects, lower doses are being tried. And delivery of aldesleukin via an inhaler, or a mechanical device that puts the compound into the air passages when a person breathes, is being used in the case of metastatic melanoma that has invaded the lungs.
Precautions
Side effects from aldesleukin are generally very severe. No one who already has a metastatic growth in the central nervous system should take the treatment because aldesleukin will incite, or aggravate, symptoms from the tumor.
